TGFB1 and metabolic dysfunction-associated steatohepatitis: In mouse models of nonalcoholic steatohepatitis (NASH), ARBs decreased activation of hepatic stellate cells and expression of TGF-β1, attenuating liver fibrosis and leading to improved survival [34–36].